Home

Sofinnova Management X, L.P.

CIK 1680194 · last filed 2023-02-27

Sofinnova Management X, L.P. is a corporate insider who has filed 4 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for CINC, was dated Feb 27, 2023. Across all open-market trades the lifetime net is +$66.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $544.0K across reported positions. The firm reports its address in Menlo Park, CA. 16 SEC filings were submitted jointly with Sofinnova Venture Partners X, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$544.0K

Companies

3

Total Filings

4

Lifetime Open-Market Net

$66.17M

Filer Profile

Reported Address
3000 SAND HILL ROAD, 4-250
MENLO PARK, CA 94025
Phone
(650) 681-8420
State of Incorporation
DE
Formerly Known As
Sofinnova Management X, L.L.C. (2020–2022)
Related Filers
Sofinnova Venture Partners X, L.P. — 16 joint filings, latest 2023-02-27
JAMES HEALY — 11 joint filings, latest 2023-02-27
Maha Katabi — 11 joint filings, latest 2023-02-27
MICHAEL POWELL — 8 joint filings, latest 2021-05-18
Inozyme Pharma, Inc. — 2 joint filings, latest 2020-07-28
SOFINNOVA VENTURE PARTNERS VI L P — same reported address
Sofinnova Management IX, L.L.C. — same reported address
Sofinnova Management VI, L.L.C. — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CinCor Pharma, Inc. (CINC) Delisted 10%+ Owner 0 $29.06 $0 $15.17M 2 2023-02-27
Jade Biosciences, Inc. (AVTE) Delisted 10%+ Owner 107,391 $93.80 $10.07M $15.00M 1 2021-07-06
BOLT 10%+ Owner 137,722 $3.95 $544.0K $36.00M 1 2021-02-09

Recent Filings

4 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-02-27 CinCor Pharma, Inc. (CINC) Delisted Mixed −30,546,800 -$429.6K EDGAR
2022-01-13 CinCor Pharma, Inc. (CINC) Delisted Mixed +16,721,847 $15.60M EDGAR
2021-07-06 Jade Biosciences, Inc. (AVTE) Delisted Mixed +11,276,058 $15.00M EDGAR
2021-02-09 BOLT Mixed +11,017,748 $36.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.